ChemoCentryx, Inc. Form SC 13G February 16, 2012

the Notes).

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

SOMESTEE 130
Under the Securities Exchange Act of 1934 (Amendment No) *
ChemoCentryx, Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
16383L 10 6
(CUSIP Number)
February 13, 2012
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
<pre>[] Rule 13d-1(b) [X] Rule 13d-1(c) [] Rule 13d-1(d)</pre>
*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be

Page 1 of 4 Pages

deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see

SCHEDULE 13G

CU	CUSIP No. 16383L 10 6 Page 2				of 4 Pages		
1	NAMES OF REPORTING PERSONS/I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)						
	Techne Corporation 41-1427402						
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS					(a) [] (b) [
3	SEC USE ONLY					_	
4	CITIZENSHIP OR PI	LACE	OF ORGANIZATION			-	
	Minnesota						
NUMBER OF SHARES BENEFICIALLY		5	SOLE VOTING POWER			_	
			6,385,056				
	REPORTING PERSON		SHARED VOTING POWER				
WITH			0				
		 7	SOLE DISPOSITIVE POWER				
			6,385,056				
		8	SHARED DISPOSITIVE POWER				
			0				
9	AGGREGATE AMOUNT	BEN	EFICIALLY OWNED BY EACH REPORTING PERSON			_	
	6,385,056						
10	CHECK IF THE AGGE		TE AMOUNT IN ROW (9) EXCLUDES CERTAIN SH	ARES	[]	_	
11	PERCENT OF CLASS	REP	RESENTED BY AMOUNT IN ROW (9)			_	
	18.0%						
12	TYPE OF REPORTING	F PE	RSON (SEE INSTRUCTIONS)				
	CO						
			Page 2 of 4 Pages			_	

Item 1(a) Name of Issuer:

ChemoCentryx, Inc.

Item 1(b) Address of Issuer's Principal Executive Offices: 850 Maude Avenue Mountain View, CA 94043 Item 2(a) Name of Person Filing: See Cover Page Item 1 Item 2(b) Address of Principal Business Office or, if none, residence: 614 McKinley Place N.E. Minneapolis, MN 55413 Item 2(c) Citizenship: See Cover Page Item 4 Item 2(d) Title of Class of Securities: Common Stock Item 2(e) CUSIP No.: See Cover Page Item 3 Statement filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c): Not applicable Item 4 Ownership See Cover Page Items 5 through 11 Ownership of Five Percent or Less of a Class: Item 5 If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following []. Page 3 of 4 Pages Ownership of More than Five Percent on Behalf of Another Person:

Not applicable

Item 9 Notice of Dissolution of Group:

Not applicable

Item 10 Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of such securities and were not acquired and are not held in connection or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 16, 2012 (Date)

/s/Thomas E. Oland ------(Signature)

Thomas E. Oland, Chief Executive Officer Techne Corporation

(Name and title)

Page 4 of 4 Pages